Phaseline

Targets › TACSTD2

TACSTD2 (Tumor-associated calcium signal transducer 2): drug programs, companies and trials

14 programs from 13 companies in 236 trials: 121 Phase 2, 70 Phase 3, 44 Phase 1, 1 Phase 4; Oncology, Gastroenterology, Genitourinary; next expected readout Nov 2026.

May function as a growth factor receptor. (UniProt, P09758)

Open in Phaseline: the race on TACSTD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaDatopotamab Deruxtecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 4Stomatitis; Breast Cancer; Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer …Dec 2026
Sichuan Baili PharmaceuticalBL-B01D1
Anti-TROP2 antibody-drug conjugate
TROP-2, TROP2, TACSTD2Phase 3Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer …Nov 2026
Sichuan Kelun-Biotech BiopharmaceuticalSacituzumab Govitecan (SKB264)
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer …Nov 2026
Gilead SciencesSacituzumab Govitecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer; Locally Advanced or Unresectable Metastatic Breast Cancer …Dec 2026
Daiichi SankyoDatopotamab Deruxtecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Non-small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Urothelial Cancer; Advanced or Metastatic NSCLC …Dec 2026
Merck & Co. (MSD)Sacituzumab Govitecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Carcinoma, Non-Small-Cell Lung; Gastroesophageal Cancer; Non-small Cell Lung Cancer (NSCLC); Breast Neoplasms …Jan 2027
RenJi Hospital[18F]F-RESCA-RCCB6
Trop2/HER2-targeted PET imaging agent
CD70, TROP2, TACSTD2, ERBB2Phase 2Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast CancerNov 2026
Klus PharmaSacituzumab Govitecan (SKB264)
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 2Non-small Cell Lung Cancer; Solid Tumor; Epithelial Ovarian CancerDec 2026
Yunnan Cancer HospitalTTP-ICG fluorescent probe
Trop2-targeted NIR-II fluorescent probe
TACSTD2Phase 2Bladder Cancer (BC)Jul 2027
Lepu BiopharmaBecotatug Vedotin for Injection
Anti-TROP-2 antibody-drug conjugate
TACSTD2Phase 2Head and Neck Squamous Cell CarcinomaDec 2027
Jeeyun LeeSonesitatug Vedotin
TROP-2-targeting antibody-drug conjugate
TACSTD2Phase 2Stomach NeoplasmsOct 2028
RenJi Hospital[18F]F-RESCA-RB14
Trop2/HER2-targeted PET imaging agent
TACSTD2, ERBB2Phase 1Breast CancerNov 2026
BiOneCure TherapeuticsBIO-106
anti-TROP-2 antibody-drug conjugate
TACSTD2Phase 1Advanced CancerApr 2027
RocheRO7851624
anti-TACSTD2 (TROP-2) antibody-drug conjugate
TACSTD2Phase 1Relapsed/Refractory Multiple MyelomaJul 2030

Conditions

Breast Cancer (23) Non-small Cell Lung Cancer (18) Non-Small Cell Lung Cancer (9) Triple Negative Breast Cancer (8) Cervical Cancer (6) Esophageal Squamous Cell Carcinoma (5) Metastatic Breast Cancer (5) Urothelial Carcinoma (4) Endometrial Cancer (4) Non-small Cell Lung Cancer (NSCLC) (4) Metastatic Breast Cancer ( HER2 Negative) (4) Triple-Negative Breast Cancer (TNBC) (3)

Modalities

mixed (6), small molecule (5), antibody (3)

Companies

RenJi Hospital (2) Sichuan Baili Pharmaceutical (1) Gilead Sciences (1) AstraZeneca (1) Merck & Co. (MSD) (1) Klus Pharma (1) Lepu Biopharma (1) Daiichi Sankyo (1) BiOneCure Therapeutics (1) Yunnan Cancer Hospital (1) Roche (1) Jeeyun Lee (1) Sichuan Kelun-Biotech Biopharmaceutical (1)

Related targets

TOP1 (6) TROP2 (2) ERBB2 (2) TROP-2 (1) CD70 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.